Odyssey Health, Inc. (ODYY) Marks New Milestone in Pursuit of Concussion Treatment with Positive Safety Findings from Cohort I of Phase 1 Clinical Trial for PRV-002
Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs The subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has no FDA-approved drug Data from Cohort I of the Phase I study showed that PRV-002 is well-tolerated, with no adverse events being observed The company believes that, if PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, the intranasal brain-targeting will be the key to its success Phase 1 and 2 drugs represent…